ASCO 2019 NSCLC - PARP & Chemotherapy

REF	Study	Study details	Line	Drug	Biomarker/Subgroup	N	Primary endpoint	Secondary endpoints
1	R000007955 UMIN000006737 (N=804)	Phase III, double-blind, randomised Resected stage II-IIIa NSCLC	Adj.	pemetrexed + cisplatin (Arm A) vinolrebin + cisplatin (Arm B)	All EGFRm+ Arm A vs B EGFRwt Arm A vs B	389 395	**mRFS** 38.9 mo NS 37.3 mo NS	**Interaction** HR=1.38 HR=0.87 } p=0.046
2	NRG-LU001 NCT02186847 (N=170)	Phase II, open-label, randomised Unresectable stage IIIA/B NSCLC Excluded: diabetes patients	1st	all CRT metformin + CRT		170	**1-yr / 2-yr PFS-rate** 60.4% / 40.1% NS 51.3% / 34.5% NS	**2-yr OS** 65.4% NS 64.9% NS
3	ECOG-ACRIN 5508 NCT01107626 (N=1516)	Phase III, open-label, randomised Stage IIIB (T4NX) NSQ-NSCLC, or Stage IV (including M1a or M1b) NSQ-NSCLC Stable or better response after induction CTx*	Maint.	CTx* —> Maint. bevacizumab CTx* —> Maint. pemetrexed CTx* —> Maint. bevacizumab + pemetrexed *carboplatin + paclitaxel +bevacizumab		287 294 293	mOS: 14.4 mo NS mOS: 15.9 mo NS mOS: 16.4 mo NS	mPFS: 4.2 mo mPFS: 5.1 mo mPFS: 7.5 mo
4	COMPASS UMIN000004194 (N=621)	Phase III, openb-label, randomised Stage IIIB or IV NSQ-NSCLC	Maint.	CTx* —> Maint. bevacizumab + pemetrexed CTx* —> Maint. bevacizumab Any *carboplatin + pemetrexed + bevacizumab	EGFR-wildtype	299 295	mOS: 23.3 mo NS mOS: 19.6 mo NS HR OS: 0.82 (0.68, 0.99)	mPFS: 5.7 mo mPFS: 4.0 mo
5	M14-360/AFT-07 NCT02412371 (N=48)	Phase II, randomised, placebo-controlled Unresectable stage III NSCLC	1st	veliparib + CRT placebo + CRT		41	mPFS: 24.1 mo	ORR: 63.4%
6	Lung-MAP S1400G NCT02154490 (N=51)	Phase II/III randomised Selected patients through S1400 platform HRRD+ stage IV SQ-NSCLC Platinum-sensitive disease	≥2nd	S1400G-arm talazoparib (BMN-673)	FEP PAP	51 47 24	 ORR: 11% mPFS: 2.5 mo mOS: 5.7 mo ORR: 4% mPFS: 2.4 mo mOS: 5.2 mo	 DCR: 53% DoR: 1.8 mo DCR: 54%

Abbreviations and citations on final slide
Data based on public abstracts and clinicaltrials.gov information

ASCO 2019 Lung - NSCLC + RET/ROS1/ALK/NTRK/KRAS

REF	Study	Study details	Line	Drug	Biomarker/Subgroup	N	Primary endpoint	Secondary endpoints
7	ARROW NCT03037385 (N=360)	Phase I, open-label, single arm Advanced NSCLC RET fusion-positive	≥1st	BLU-667	All Prior platinum CTx	57 30	ORR: 56% (all PR) ORR: 60% (all PR)	DCR: 91%
8	TRIDENT-1 NCT03093116 (N=75)	Phase I, open-label, single arm laNSCLC or mNSCLC TKI-naïve and TKI-refractory ROS1/NTRK/ALK+ disease	≥1st	repotrectinib (TPX-0005)	ROS1+ - TKI naïve - Prior TKI - Prior TKI & DL ≥160mg qd ROS1+ & CNS lesions	28 10 18 9 3	**ORR** 90% (BCR) 28% (BCR) 44% iORR: 100%	**mDoR** NR 10.2 mo iDoR: 5.5 mo
9	B7461001 NCT01970865 (N=334)	Phase II, open-label ALK+ NSCLC	≥1st	lorlatinib	VAF BL ALK alterations CR/PR SD PD ΔVAF<0 (decrease ALK VAF) ΔVAF≥0 (increase ALK VAF)	57 40 44 34 13 13 13		C3D1 ΔVAF: -1.07 C3D1 ΔVAF: -1.84 C3D1 ΔVAF: -0.74 NS C3D1 ΔVAF: +0.35 NS TVM: -26% mPFS: 6.6 mo mOS: 18.0 mo TVM: -12% mPFS: 2.6 mo mOS: 8.6 mo
10	S1507 NCT02642042 (N=54)	Phase II, open-label Stage IV or recurrent NSCLC KRAS mutation at codon 12,13 and 61	≥1st	trametinib + docetaxel	All G12C Non-G12C	54 19 35	**ORR** 33% 26% 37%	**mPFS / mOS** 4.1 mo / 11.1 mo 3.3 mo / 8.8 mo 4.1 mo / 16.3 mo

Abbreviations and citations on final slide
Data based on public abstracts and clinicaltrials.gov information

ASCO 2019 Lung - NSCLC + cMET

REF	Study	Study details	Line	Drug	Biomarker/Subgroup	N	Primary endpoint	Secondary endpoints
11	CINC280A2201 NCT02414139 (N=364)	Phase II, open-label Stage IIIB or IV NSCLC EGFRwt/ALK-	 ≥2nd 1st	 capmatinib (INC280) in pre-treated patients capmatinib (INC280) in treatment-naïve patients	 Ch4: METΔex14 mutation Ch5b: METΔex14 mutation	 69 28	**ORR** 39.1% 71.4%	**mDoR / mPFS** 9.72 mo / 5.42 mo 8.41 mo / 9.13 mo
12	VISION NCT02864992 (N=120)	Phase II, single arm Stage IIIB or IV NSCLC EGFRwt/ALK- METΔex14 mutation	≥1st	tepotinib	 Liquid biopsy - 1st line - 2nd line - ≥3rd line Tumor biopsy - 1st line - 2nd line - ≥3rd line	 35 12 11 12 41 16 12 13	**ORR / mDoR** 51.4% / 9.8 mo 66.7% 54.5% 33.3% 41.5% / 12.4 mo 37.5% 50.0% 38.5%	**IA ORR / IA mDoR** 63.9% / 17.1 mo 91.7% 58.3% 41.7% 58.5% / 14.3 mo 53.3% 69.2% 53.8%
13	CR108064 NCT02609776 (N=116)	Phase I, open-label, single arm Unresectable or mNSCLC	≥1st	JNJ-61186372 (JNJ-372)	 All evaluable (97% EGFRm) - Prior EGFR 3GTKI - EGFR Ex20ins	 88 47 20		**ORR** 28% (all PR) 21% (all PR, 6 conf.) 30% (all PR, 3 conf.)
14	M14-237 NCT02099058 (N=238)	Phase I/Ib NSCLC not amenable to surgery No viable treatment options available cMET overexpression by SP44 antibody, or FISH MET/CEP7 ratio ≥2, or Whole-exome sequencing —> MET GCN ≥2	≥1st	teliso-v (ABBV-399) Q2W teliso-v (ABBV-399) Q3W teliso-v + erlotinib	NSQ-NSCLC - H-S ≥150 - H-S ≥150 & < 225 - H-S ≥225 SQ-NSCLC - H-S ≥150 - H-S ≥150 & < 225 - H-S ≥225 EGFRm+ - H-S ≥150 - H-S ≥150 & < 225 - H-S ≥225	 16 9 7 17 9 8 28 12 16		**ORR / mPFS** 37.5% / 5.2 mo 33.3% / 5.2 mo 42.9% / 8.0. mo 11.8% / 2.7 mo 11.0% / 1.4 mo 12.5% / NR 35.7% / 5.3 mo 16.7% / 3.7 mo 50.0% / NR

Abbreviations and citations on final slide
Data based on public abstracts and clinicaltrials.gov information

ASCO 2019 Lung - EGFRm+ NSCLC (1)

REF	Study	Study details	Line	Drug	Biomarker/Subgroup	N	Primary endpoint	Secondary endpoints
15	12-504 NCT01746251 (N=60)	Phase II, randomised Resected Stage I-III EGFRm+ NSCLC Note: terminated for tolerability & recruitment	Adj.	Any 3-mo afatinib 2-yr afatinib	All	46	 mRFS: NR mRFS: NR	
16	U31402-A-U102 NCT03260491 (N=15)	Phase I, open-label, single arm laNSCLC or mNSCLC EGFR TKI resistance (Jackman criteria)	≥2nd	U3-1402		13	92.3% decrease SLD PR: 15.4%	
17	RELAY NCT02411448 (N=543)	Phase III, double-blind, randomised Stage IV NSCLC EGFRm+ (Ex19del or L858R)	1st	 ramucirumab + erlotinib placebo + erlotinib Any	 All	 224 225 449	**mPFS** 19.4 mo 12.4 mo	**ORR / DoR / mOS / PFS2** 76.3% / 18.0 mo / NR / NR 74.7% / 11.1 mo / NR / NR PFS2 HR: 0.690 (0490, 0.972)

ASCO 2019 Lung - EGFRm+ NSCLC (2)

REF	Study	Study details	Line	Drug	Biomarker/Subgroup	N	Primary endpoint	Secondary endpoints
18	CTRI/ 2016/08/007149 (N=350)	Phase III, randomised Stage IV NSCLC EGFRm+ (Exon 19, 21, or 18) CTx-naïve	≥1st	 gefitinib + pemetrexed + carboplatin gefitinib		 177 173	**mPFS** 16 mo 8 mo	**ORR / mOS** 81% / NR 69% / 18.0 mo
19	AP32788-15-101 NCT02716116 (N=101)	Phase I/II, open-label Stage IIIB or IV NSCLC	≥3rd	TAK-788 (AP32788)	Dose escalation or expansion Ch 1 EGFR Ex20ins	26	ORR: 54% (all PR)	DCR: 89%
20	FLAURA NCT02296125 (N=674)	Phase III, double-blind, randomised laNSCLC or mNSCLC EGFRm+ (Ex19del or L858R)	1st	 All osimertinib gefitinib or erlotinib	 BL detectable EGFR ctDNA 3-wk detectable EGFR ctDNA 3-wk undetectable EGFR ctDNA 6-wk detectable EGFR ctDNA 6-wk undetectable EGFR ctDNA BL detectable EGFR ctDNA 3-wk detectable EGFR ctDNA 3-wk undetectable EGFR ctDNA 6-wk detectable EGFR ctDNA 6-wk undetectable EGFR ctDNA BL detectable EGFR ctDNA 3-wk detectable EGFR ctDNA 3-wk undetectable EGFR ctDNA 6-wk detectable EGFR ctDNA 6-wk undetectable EGFR ctDNA	 342 126 208 69 258 168 56 106 30 134 174 70 102 39 124	**mPFS** 9.5 mo 13.5 mo 8.3 mo 13.5 mo 11.3 mo 19.8 mo 11.1 mo 19.8 mo 7.0 mo 10.8 mo 8.2 mo 10.2 mo	

Abbreviations and citations on final slide
Data based on public abstracts and clinicaltrials.gov information

ASCO 2019 Lung - NSCLC Immunotherapy (1)

REF	Study	Study details	Line	Drug	Biomarker/Subgroup	N	Primary endpoint	Secondary endpoints
21	Lung-MAP S1400I NCT02785952 (N=350)	Phase III, randomised Stage IV SQ-NSCLC	≥2nd				**mOS**	**IA mPFS / ORR**
				nivolumab+ipilimumab	All	125	10.0 mo NS	3.8 mo NS / 18%
					PD-L1 ≥5		14.1 mo NS	3.9 mo NS
					PD-L1 <5		8.3 mo NS	4.4 mo NS
					TMB ≥10		13.1 mo NS	4.2 mo NS
					TMB <10		7.6 mo NS	1.9 mo NS
				nivolumab	All	127	11.0 mo NS	2.9 mo NS / 19%
					PD-L1 ≥5		12.0 mo NS	2.9 mo NS
					PD-L1 <5		10.3 mo NS	1.6 mo NS
					TMB ≥10		11.4 mo NS	3.4 mo NS
					TMB <10		10.0 mo NS	2.7 mo NS
22	KEYNOTE-189 NCT02578680 (N=616)	Phase III, double-blind, randomised Stage IV NSQ-NSCLC	1st	Arm A: pembrolizumab + pemetrexed + carboplatin or cisplatin		410	mOS: 22.0 mo	
				Arm B: placebo + pemetrexed + carboplatin or cisplatin		206	mOS: 10.7 mo	
							HR Arm A vs Arm B	**HR Arm A vs Arm B**
				Arm A + Arm B	All	616	OS: 0.56 (0.45, 0.70) PFS: 0.48 (0.40, 0.58)	
					- TPS ≥50%	202	OS: 0.59 (0.39, 0.88) PFS: 0.36 (0.26, 0.51)	PFS2: 0.47 (0.33, 0.69)
					- TPS 1%–49%	186	OS: 0.62 (0.42, 0.92) PFS: 0.51 (0.36. 0.73)	PFS2: 0.59 (0.41, 0.86)
					- TPS <1%	190	OS: 0.52 (0.36, 0.74) PFS: 0.64 (0.47, 0.89)	PFS2: 0.46 (0.33, 0.66)
23	KEYNOTE-001 NCT01295827 (N=550)	Phase Ib, open-label, randomised laNSCLC or mNSCLC	≥1st				**ORR / median DoR**	**mOS / OS-rate 36- / 60-mo**
				pembrolizumab	All	550		
					Treatment-naïve	101	42% / 16.8 mo	22.3 mo / 37& / 23.2%
					- TPS ≥50%	27		35.4 mo / 48.1% / 29.6%
					- TPS 1%–49%	52		19.5 mo / 27.5% / 15.7%
					Prior treatment(s)	449	23% / 38.9 mo	10.5 mo / 20.9% / 15.5%
					- TPS ≥50%	138		15.4 mo / 30.4% / 25.0%
					- TPS 1%–49%	168		8.5 mo / 16.9% / 12.6%
					- TPS <1%	90		8.6 mo / 11.1% / 3.5%

Abbreviations and citations on final slide
Data based on public abstracts and clinicaltrials.gov information

Abbreviations and citations on final slide
Data based on public abstracts and clinicaltrials.gov information

ASCO 2019 Lung - NSCLC Immunotherapy (2)

REF	Study	Study details	Line	Drug	Biomarker/Subgroup	N	Primary endpoint	Secondary endpoints
24	IMpower150 NCT02366143 (N=1202)	Phase III, open-label, randomised Stage IV NSQ-NSCLC No prior treatment for stage IV NSCLC	1st		**Liver metastases**		**mPFS / mOS**	**ORR (N) / median DoR (N)**
				atezolizumab + carboplatin + paclitaxel + bevacizumab	- No	348	8.4 mo / 20.4 mo	55.8% (346) / 11.5 mo (193)
					- Yes	52	8.2 mo / 13.3 mo	60.8% (51) / 10.7 mo (31)
				atezolizumab + carboplatin + paclitaxel	- No	349	6.9 mo / 21.0 mo	42.7% (349) / 9.2 mo (149)
					- Yes	53	5.4 mo / 8.9 mo	26.9% (52) / 5.6 mo (15)
				carboplatin + paclitaxel + bevacizumab	- No	343	7.0 mo / 17.0 mo	40.1% (337) / 6.5 mo (138)
					- Yes	57	5.4 mo / 9.4 mo	41.1% (56) / 4.6 mo (23)
25	MYSTIC NCT02453282 (N=1118)	Phase III, open-label, randomised Stage IV NSCLC No prior trearment for recurrent/ mNSCLC	1st				**HR for OS vs SOC CTx***	
				durvalumab	PD-L1 TC ≥25%	163	0.76 (0.56, 1.02)	
					- BL TMB ≥20	40	0.79 (0.45, 1.39)	
					- BL TMB <20	91	0.64 (0.45, 0.90)	
					PD-L1 TC ≥1%	279	0.88 (0.73, 1.07	
					- BL TMB ≥20	61	0.74 (0.48, 1.13)	
					- BL TMB <20	152	0.79 (0.61, 1.03)	
					PD-L1 TC <1%	95	1.18 (0.86, 1.62)	
					- BL TMB ≥20	16	0.68 (0.32, 1.42)	
					- BL TMB <20	57	1.38 (0.89, 2.18)	
				durvalumab + tremelimumab	PD-L1 TC ≥25%	163	0.85 (0.61, 1.17)	
					- BL TMB ≥20	32	0.44 (0.23, 0.84)	
					- BL TMB <20	81	1.16 (0.83, 1.63)	
					PD-L1 TC ≥1%	296	1.01 (0.83, 1.21)	
					- BL TMB ≥20	49	0.52 (0.32, 0.83)	
					- BL TMB <20	164	1.21 (0.95, 1.55)	
					PD-L1 TC <1%	76	0.73 (0.51, 1.04)	
					- BL TMB ≥20	15	1.21 (0.95, 1.55)	
					- BL TMB <20	40	0.99 (0.60, 1.62)	
				*SOC platinum-based CTx				
26	LCMC3 NCT02927301 (N=180)	Phase II, open-label, single arm Stages IB to IIIB resectable NSCLC	Neo	atezolizumab	All	90		
					- EGFRwt	82	MPR-rate: 18%	pCR-rate: 5% PR-rate: 7% SD-rate: 88%
					- PD-L1- (SP142)	26	MPR-rate: 8%	
					- PD-L1+ (SP142)	35	MPR-rate: 29%	
					- TPS<50 (22C3)	44	MPR-rate: 11%	
					- TPS>50 (22C3)	20	MPR-rate: 35%	

ASCO 2019 Lung - NSCLC Immunotherapy (3)

REF	Study	Study details	Line	Drug	Biomarker/Subgroup	N	Primary endpoint	Secondary endpoints
27	NEOSTAR NCT03158129 (N=66)	Phase II, open-label, randomised Stages IB to IIIA (single N2) NSCLC	Neo	nivolumab or nivolumab + ipilimumab	All	41	MPR-rate: 24%	pCR-rate: 15% ORR: 22% CR: 2% PR: 20% PD: 37%
					- All resected	34	MPR-rate: 29%	
				nivolumab	All nivolumab	22		pCR-rate: 9%
					- resected	UNK	MPR-rate: 20%	
				nivolumab + ipilimumab	All nivolumab + ipilimumab	19		pCR-rate: 21%
					- resected	UNK	MPR-rate: 43%	
28	GECP16/03_NADIM NCT03081689 (N=46)	Phase II, open-label, single arm Stage IIIA N2 NSCLC	Neo	nivolumab + paclitaxel + carboplatin	All resected	41		MPR: 83% pCR: 71% PR: 29% CR: 7% Downstaged: 90%
29	NCI-2015-01810 NCT02621398 (N=30)	Phase I, 3+3 cohort study Stage II-IIIB NSCLC	1st	pembrolizumab + CRT—> Maint. pembrolizumab	All ≥2 doses pembrolizumab	23 18		mPFS: not reported mPFS: 20.3 mo
30	DETERRED NCT02525757 (N=52)	Phase II Non-metastatic, unresectable NSCLC	1st	CRT*—> CTx*-atezolizumab —> atezolizumab atezolizumab + CRT*—> CTx*-atezolizumab —> atezolizumab	All	40 10 30		1-yr PFS/1-yr OS 50% NS / 79% NS 57% NS / 79% NS
					All PD-L1<1% (22C3)	16		RR: 44% NS
					All PD-L1≥1% (22C3)	18		RR: 33% NS
					All PD-L1<50% (22C3)	26		RR: 42% NS
					All PD-L1≥50% (22C3)	8		RR: 25% NS
				*carboplatin + paclitaxel				

Abbreviations and citations on final slide
Data based on public abstracts and clinicaltrials.gov information

ASCO 2019 Lung - Malignant Pleural Mesothelioma

REF	Study	Study details	Line	Drug	Biomarker/Subgroup	N	Primary endpoint	Secondary endpoints
31	CALGB 30901 NCT01085630 (N=72)	Phase II, open-label, randomised MPM with CR, PR, or SD after 4-6 cycles of 1st-line pemetrexed + platinum	Maint.	All pemetrexed clinical observation	 SMRP-high vs low @ BL Osteopontin-high vs low @ BL	49 27 22	**mPFS** 3.4 mo NS 3.0 mo NS PFS HR: 1.861 NS	**mOS** 16.3 mo NS 11.8 mo NS
32	R000010666 UMIN000009092 (N=24)	Single-arm feasibility study T0-3, N0-2, M0 MPM	1st	Induction pemetrexed + cisplatin —> pleurectomy/ decortication		20	MCR-rate: 90%	1-yr OS-rate: 95.0% 2-yr OS-rate: 70.0% mOS: 41.4 mo 1-yr PFS-rate: 84.7% 2-yr PFS-rate: 42.4% mPFS: 22.9 mo

Abbreviations and citations on final slide
Data based on public abstracts and clinicaltrials.gov information

ASCO 2019 Lung - SCLC (1)

REF	Study	Study details	Line	Drug	Biomarker/Subgroup	N	Primary endpoint	Secondary endpoints
33	Winship3112-15 NCT02701400 (N=17)	Phase II, randomised, open-label Recurrent SCLC	2nd	durvalumab + tremelimumab +/- RTx durvalumab + tremelimumab durvalumab + tremelimumab + RTx	All evaluable	14 8 7	PR: 14% SD: 21% PD: 64% mPFS: 2.1 mo NS mOS: 2.6 mo NS mPFS: 3.3 NS mOS: 5.7 mo NS	
34	M16-300 NCT03026166 (N=42)	Phase I, non-randomised Extensive-stage SCLC DLL3-expression	≥2nd	rova-t + nivolumab rova-t + nivolumab + ipilimumab		30 12		ORR: 23% mDoR: 3.8 mo mPFS: 4.8 mo mOS: 7.2 mo ORR: 33% mDoR: 3.3 mo mPFS: 4.1 mo mOS: 7.0 mo
35	CAR-IST-553 NCT01941316 (N=112)	Phase II, open-label Relapsed extensive-stage SCLC One platinum CTx without maintenance	2nd	carfilzomib + irinotecan	 Platinum-refractory Platinum-sensitive	62	 6-mo OS: 54% mOS: 6.8 mo 6-mo OS: 59% mOS: 6.9 mo	 ORR: 12.5% DCR: 56% PFS: 3.3 mo ORR: 21.6% DCR: 68% PFS: 3.6 mo

Abbreviations and citations on final slide
Data based on public abstracts and clinicaltrials.gov information

ASCO 2019 Lung - SCLC (2)

REF	Study	Study details	Line	Drug	Biomarker/Subgroup	N	Primary endpoint	Secondary endpoints
36	PM1183-B-005-14 NCT02454972 (N=105)	Phase II, single arm, basket study One prior line of chemotherapy for SCLC	≥2nd	lurbinectedin (PM01183)	All	105	ORR: 35.2%	DCR 8-wk: 64.8% DOR: 5.3 mo DOR 6-mo: 40.3% DOR 12-mo: 10.6% mOS: 10.8 mo
					CTFI<90days	47	ORR: 21.3%	DCR 8-wk: 46.8% DOR: 4.7 mo DOR 6-mo: 11.7% DOR 12-mo: - mOS: 5.1 mo
					CTFI≥90days	58	ORR: 46.6%	DCR 8-wk: 79.3% DOR: 6.2 mo DOR 6-mo: 50.3% DOR 12-mo: 14.7% mOS: 15.2 mo

Abbreviations and citations on final slide
Data based on public abstracts and clinicaltrials.gov information

References & Abbreviatons

1. Kenmotsu H, et al. J Clin Oncol 37, 2019 (suppl; abstr 8501)	13. Haura EB, et al. J Clin Oncol 37, 2019 (suppl; abstr 9009)	25. Rizvi NA, et al. J Clin Oncol 37, 2019 (suppl; abstr 9016)
2. Tsakiridis T, et al. J Clin Oncol 37, 2019 (suppl; abstr 8502)	14. Suk Heist R, et al. J Clin Oncol 37, 2019 (suppl; abstr 9023)	26. Kwiatkowski DJ, et al. J Clin Oncol 37, 2019 (suppl; abstr 8503)
3. Ramalingam SS, et al. J Clin Oncol 37, 2019 (suppl; abstr 9002)	15. Chaft JE, et al. J Clin Oncol 37, 2019 (suppl; abstr 8507)	27. Cascone T, et al. J Clin Oncol 37, 2019 (suppl; abstr 8504)
4. Seto T, et al. J Clin Oncol 37, 2019 (suppl; abstr 9003)	16. Janne PA, et al. J Clin Oncol 37, 2019 (suppl; abstr 9010)	28. Provencio-Pulla M, et al. J Clin Oncol 37, 2019 (suppl; abstr 8509)
5. Kozono DE, et al. J Clin Oncol 37, 2019 (suppl; abstr 8510)	17. Nakagawa K, et al. J Clin Oncol 37, 2019 (suppl; abstr 9000)	29. Jabbour SK, et al. J Clin Oncol 37, 2019 (suppl; abstr 8511)
6. Owonikoko TK, et al. J Clin Oncol 37, 2019 (suppl; abstr 9022)	18. Noronha V, et al. J Clin Oncol 37, 2019 (suppl; abstr 9001)	30. Lin SH, et al. J Clin Oncol 37, 2019 (suppl; abstr 8512)
7. Gainor JF, et al. J Clin Oncol 37, 2019 (suppl; abstr 9008)	19. Janne PA, et al. J Clin Oncol 37, 2019 (suppl; abstr 9007)	31. Dudek AZ, et al. J Clin Oncol 37, 2019 (suppl; abstr 8517)
8. Cho BC, et al. J Clin Oncol 37, 2019 (suppl; abstr 9011)	20. Zhou C, et al. J Clin Oncol 37, 2019 (suppl; abstr 9020)	32. Hasegawa S, et al. J Clin Oncol 37, 2019 (suppl; abstr 8518)
9. Tsang Shaw A, et al. J Clin Oncol 37, 2019 (suppl; abstr 9019)	21. Bazhenova L, et al. J Clin Oncol 37, 2019 (suppl; abstr 9014)	33. Owonikoko TK, et al. J Clin Oncol 37, 2019 (suppl; abstr 8515)
10. Gadgeel SM, et al. J Clin Oncol 37, 2019 (suppl; abstr 9021)	22. Gadgeel SM, et al. J Clin Oncol 37, 2019 (suppl; abstr 9013)	34. Malhotra J, et al. J Clin Oncol 37, 2019 (suppl; abstr 8516)
11. Wolf J, et al. J Clin Oncol 37, 2019 (suppl; abstr 9004)	23. Garon EB, et al. J Clin Oncol 37, 2019 (suppl; abstr LBA9015)	35. Arnold SM, et al. J Clin Oncol 37, 2019 (suppl; abstr 8513)
12. Paik PK, et al. J Clin Oncol 37, 2019 (suppl; abstr 9005)	24. Socinski MA, et al. J Clin Oncol 37, 2019 (suppl; abstr 9012)	36. Paz-Ares LG, et al. J Clin Oncol 37, 2019 (suppl; abstr 8506)

Abbreviations: ΔVAF, difference between VAF BL and VAF C3D1; 3GTKI, third generation TKI; Adj., adjuvant; ALK+, anaplastic lymphoma kinase rearranged; ALK-, anaplastic lymphoma kinase rearrangement negative; BCR, blinded central review; BL, baseline; BSC, best supportive care; C3D1, cycle 3 day 1; CEP7, centromeric region of chromosome 7; Ch, cohort; cMET, MET or hepatocyte growth factor receptor; CNS, central nervous system; conf., confirmed; CR, complete response; CRT, chemo-radiation therapy; CTFI, median chemotherapy-free interval; CTx, chemotherapy; DCR, disease control rate; DL, dose level; DLL3, cancer stem cell-associated target delta-like protein 3; EGFR, endothelial growth factor receptor; EGFR Ex19del, EGFR exon 19 deletion; EGFR Ex20ins, EGFR exon 20 insertion; EGFRm, EGFR mutation; EGFRm+; EGFRm-positive; EGFRwt, EGFR wildtype; FEP, full eligible population; FISH, fluorescent in-situ hybridisation; G12C, KRAS missense codon 12 glycine to cysteine; GNC, gene-copy number; HR, hazard ratio; HRR, homologous recombination repair; HRRD+, HRR deficiency-positive; H-S, membrane H-score; IA, investigator-assessed; iDoR, intracranial DoR; iORR, intracranial ORR; KRAS, Kirsten rat sarcoma viral oncogene homolog; laNSCLC, locally advanced NSCLC; Maint., maintenance; MCR, macroscopic complete resection; mDoR, median duration of response; MET, cMET or hepatocyte growth factor receptor; METΔex14, MET exon 14 skipping mutations; mNSCLC, metastatic NSCLC; mo, months; mOS, median OS; MPM, malignant pleural mesothelioma; MPR, major pathological response; mPFS, median PFS; mRFS, median recurrence-free survival; Neo, neo-adjuvant; NR, not reached; NS, non-significant; NSCLC, non-small cell lung cancer; NSQ, non-squamous; NTRK1-3+, neurotrophin receptor kinase 1-3 rearranged; ORR, overall response rate; OS, overall survival; PAP, primary analysis population; pCR, pathological complete response; PD, progressive disease; PD-L1, programmed death 1 ligand; PFS, progression-free survival; PFS2: PFS after subsequent treatment; PR, partial response; qd, once daily; ROS1+, c-ros oncogene 1 rearranged; rova-t, rovalpituzumab tesirine; RR, recurrence rate; QxW, every x weeks; RTx, radiotherapy; SCLC, small cell lung cancer; SD, stable disease; SLD, sum of longest diameter; SMRP, serum mesothelin related peptide; SOC, standard-of-care; SQ, squamous; TC, tumor cells; teliso-v, telisotuzumab vedotin; TKI, tyrosine kinase inhibitor; TPS, tumor proportion score; TVM, tumour volume mass; UNK, unknown; VAF, variant allele fraction; wk, week(s).